Product Description
Cetirizine is used to temporarily relieve the symptoms of hay fever (allergy to pollen, dust, or other substances in the air) and allergy to other substances (such as dust mites, animal dander, cockroaches, and molds). These symptoms include sneezing; runny nose; itchy, red, watery eyes; and itchy nose or throat. Cetirizine is also used to treat itching and redness caused by hives. However, cetirizine does not prevent hives or other allergic skin reactions. Cetirizine is in a class of medications called antihistamines. It works by blocking the action of histamine, a substance in the body that causes allergic symptoms. (Sourced from: https://medlineplus.gov/druginfo/meds/a698026.html)
Mechanisms of Action: H1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: Europe
Company Founding Year: 2000
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, Germany
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Urticaria|Conjunctivitis, Allergic|Rhinitis, Allergic
Phase 1: Environmental Hypersensitivity|Rhinitis, Allergic, Perennial|Rhinitis, Allergic, Seasonal|Urticaria
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04071821 |
P001-2019 | P1 |
Not yet recruiting |
Environmental Hypersensitivity |
2025-07-15 |
50% |
2024-07-23 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
NCT06819774 |
Phase III | P3 |
Recruiting |
Acute Urticaria |
2025-08-01 |
11% |
2025-02-12 |
Primary Endpoints|Treatments |
2024-515717-17-00 |
T502-SIT-073 | P3 |
Active, not recruiting |
Conjunctivitis, Allergic|Rhinitis, Allergic |
2025-06-13 |
2025-05-02 |
Treatments |
|
CTR20171246 |
CTR20171246 | P1 |
Recruiting |
Urticaria|Conjunctivitis, Allergic|Rhinitis, Allergic, Seasonal|Rhinitis, Allergic, Perennial |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/10/2026 |
News Article |
TerSera Therapeutics Announces Closing of Divestiture of Infusion Specialty Therapies Business Unit to ESTEVE |
|
03/03/2026 |
News Article |
ZYRTEC® Joins PGA TOUR as the First Official Allergy Relief Sponsor |
|
01/15/2026 |
News Article |
Kick off 2026 With the Top 25 Hottest FSA- and HSA-eligible Products from FSA Store® and HSA Store® |
|
01/13/2026 |
News Article |
ESTEVE to Acquire TerSera Therapeutics' Infusion Specialty Therapies Business Unit, Expanding U.S. Presence |